Opus Genetics, Inc. annual report, FY2019

Filing identity and reporting period

Important mismatch: The supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-K, not an Opus Genetics, Inc. filing. It reports the fiscal year ended December 31, 2019; it is an annual report, not a standalone fourth-quarter report.

Business context

Rexahn was a clinical-stage oncology biopharmaceutical company with no approved products or product sales. Its principal programs included RX-3117, RX-5902 and RX-0301. In September 2019, the company began evaluating strategic alternatives—including a merger, acquisition, asset sale or licensing—and reduced its workforce to five employees.

Financial results and liquidity

At December 31, 2019, cash and cash equivalents were $9.22 million and marketable securities were $3.00 million, totaling approximately $12.22 million. Current assets were $12.66 million and current liabilities were $2.91 million. Total liabilities were $3.01 million, including operating lease liabilities, warrant liabilities, accounts payable and accrued expenses, and deferred revenue; the balance sheet reports no borrowings. Management said available cash and marketable securities were expected to fund current activities for at least 12 months after the financial statements were issued, but needs could change with a strategic transaction.

No product revenue means operating margins from product sales are not applicable. The company reported no income tax provision. It recorded a $2.27 million noncash unrealized gain on warrant liabilities in 2019, compared with $5.55 million in 2018.

Changes and notable developments

• R&D expense fell 58.2%, primarily due to completed trial enrollment, lower manufacturing costs, discontinued preclinical work and workforce reductions. G&A expense fell 22.8%, mainly from lower personnel and operating costs.
• Net loss narrowed 39.9%, reflecting lower expenses and other income, including warrant revaluation gains. These gains were noncash and depended on fair-value estimates.
• Operating cash use decreased year over year; financing provided $7.65 million in 2019, primarily from the January public offering. The offering issued 895,834 shares and warrants for up to 895,886 shares.
• RX-3117’s first-line metastatic pancreatic cancer combination trial had reached target enrollment. Preliminary, unaudited results reported a 23% response rate among 40 patients with at least one on-treatment scan and median progression-free survival of approximately 5.4 months; complete data was expected in 2020. No further pancreatic cancer trials were then planned.
• The BioSense RX-3117 agreement had a $3.0 million upfront payment, of which $1.5 million had been received; the remaining $1.5 million was unpaid at year-end. No revenue was recognized because the relevant performance obligations had not been satisfied.
• After year-end, on February 8, 2020, Rexahn licensed RX-0201, RX-0301 and RX-0047 worldwide to HaiChang, subject to specified territorial rights. The agreement provides for a $250,000 upfront payment for materials, potential development milestones and royalties; these are contingent and not assured proceeds.

Outlook, risks and contingencies

Management expected R&D expense to decline further in 2020 as it completed the RX-3117 trial, assessed RX-5902’s development strategy and pursued strategic alternatives. RX-5902’s proposed combination trial with KEYTRUDA remained uncertain; the company said it might not proceed. The filing provides no committed transaction, product-revenue forecast or definitive development plan.

Key risks include limited cash and ongoing operating losses, dependence on additional financing or successful partnerships, uncertain clinical and regulatory outcomes, reliance on third-party research and manufacturers, and the possibility that strategic alternatives may not produce a transaction or shareholder value. The company stated that failure to complete a transaction could lead its board to consider dissolution and liquidation. It reported no legal proceedings considered likely to have a material adverse effect. Estimated costs to complete existing R&D vendor agreements were approximately $1.75 million at year-end; a separate $1 million KRICT milestone is contingent on marketing approval.

Most important facts to verify

• Confirm the issuer: this filing identifies Rexahn Pharmaceuticals, Inc. (ticker REXN), not Opus Genetics, Inc.
• Review the audited financial statements and notes for cash runway, warrant valuation assumptions and the distinction between cash balance and available marketable securities.
• Check the status and collection of BioSense’s unpaid $1.5 million upfront balance and the conditions for any future milestones or royalties.
• Verify subsequent developments for the HaiChang license, strategic-alternatives process and RX-3117/RX-5902 programs; potential payments and trial outcomes were not assured.